Client of a consultant lobbyist
GlaxoSmithKline Inc.
- Meetings this Parliament
- 7
- With MPs
- 1
- Since Nov 2021
- 22
- Active registrations
- 0
Most recent reported meeting: Nov 25, 2025.
Lobbying by GlaxoSmithKline Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
GlaxoSmithKline Inc. has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by John Delacourt · Consultant
- Salma Zahid · Member of Parliament
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
-
Reported by John Delacourt · Consultant
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
-
Reported by John Delacourt · Consultant
- Jade Mallette · Policy advisor, Health Canada (HC)
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
-
Reported by John Delacourt · Consultant
- Neeraj Bhalla · Policy advisor, Global Affairs Canada (GAC)
Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Read more
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
-
Reported by John Delacourt · Consultant
- Galen Richardson · Director of Policy, Intergovernmental Affairs Secretariat (IGA)
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Read more
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
-
Reported by John Delacourt · Consultant
- Lisa Jorgensen · Senior Advisor, Prime Minister's Office (PMO)
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Read more
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
-
Reported by John Delacourt · Consultant
- Kyle Fox · Policy Advisor, Finance Canada (FIN)
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Read more
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
-
Reported by John Delacourt · Consultant
- Brian Clow · Senior Advisor, Prime Minister's Office (PMO)
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
-
Reported by John Delacourt · Consultant
- Éric Nicol · Policy advisor, Employment and Social Development Canada (ESDC)
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR. Read more
-
Reported by John Delacourt · Consultant
- Laurel Chester · Sr Advisor, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by John Delacourt · Consultant
- Victor Kandasamy · Policy Advisor & Senior advisor, Public Services and Procurement Canada (PSPC)
HealthIndustry
-
Reported by John Delacourt · Consultant
- Laurel Chester · Sr Advisor, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by John Delacourt · Consultant
- Dani Saad · Senior Policy Advisor, Prime Minister's Office (PMO)
HealthIndustry
-
Reported by John Delacourt · Consultant
- Eshan Naik · Director of Policy, Health Canada (HC)
HealthIndustry
-
Reported by John Delacourt · Consultant
- Cid Cabillan · Policy Advisor, Immigration, Refugees and Citizenship Canada (IRCC)
Health
-
Reported by John Delacourt · Consultant
- Joanna Lam · Policy Advisor, Indigenous Services Canada (ISC)
Government Procurement
-
Reported by John Delacourt · Consultant
- Mary-Rose Brown · Policy Advisor, Public Services and Procurement Canada (PSPC)
- Victor Kandasamy · Policy Advisor, Public Services and Procurement Canada (PSPC)
Government Procurement
-
Reported by John Delacourt · Consultant
- Paul Hershaw · Policy Advisor, Employment and Social Development Canada (ESDC)
Economic DevelopmentInternal Trade
-
Reported by John Delacourt · Consultant
- Bianca Hossain · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentGovernment ProcurementHealth
-
Reported by John Delacourt · Consultant
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
Economic DevelopmentGovernment ProcurementHealth
-
Reported by John Delacourt · Consultant
- Jamie Kippen · Chief of Staff, Health Canada (HC)
Government ProcurementHealth
-
Reported by John Delacourt · Consultant
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
Government ProcurementHealth
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.